Mainly, poor correlation of FGFR1 amplification with FGFR1 gene and protein expression in Sq-NSCLC cells, and ambiguous response to FGFR1 inhibition affected either due to the FGFR1 expression or presence of other alternations and subsequent activation of alternative signaling pathways, might indicate that FGFR1 amplification is a passenger alteration event rather than a driver alteration. Here, FGFR1 is linked to non-small cell lung carcinoma.